Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › BDTX

Black Diamond Therapeutics

BDTX Lead: Phase 2 1 Biotech Distilled article ↓ 10 filings & releases ↓ Cash $19.2M (Jun 30, 2026) ↓ 1 verdict ↓
Oncology Small Molecule

Market cap $99.7M 57.5M shares (10-Q, Jul 30, 2026) × $1.74 close Nov 6, 2026

Most recent annual filing: 2026-03-16

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. Silevertinib FDA feedback4Q 2026Silevertinib FDA feedback, 4Q 2026, major
  2. Silevertinib Ph2 readout4Q 2026Silevertinib Ph2 readout, 4Q 2026, material
  3. BH-30643 BlossomHill FDA feedback4Q 2026BH-30643 BlossomHill FDA feedback, 4Q 2026, notable
  4. Silevertinib Ph2 start4Q 2026Silevertinib Ph2 start, 4Q 2026, routine
  5. Silevertinib EP opposition deadline~Dec 11, 2026Silevertinib EP opposition deadline, ~Dec 11, 2026, routine
  6. Black Diamond corporate China decisionDec 18, 2026Black Diamond corporate China decision, Dec 18, 2026, material
  7. Silevertinib GBM Ph2 interim1H 2028Silevertinib GBM Ph2 interim, 1H 2028, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

MAP · Revelio Therapeutics

Mutation-Allostery-Pharmacology (MAP) drug discovery engine used to identify and develop MasterKey therapies targeting families of oncogenic mutations in cancer; also licensed to Revelio Therapeutics for large molecule therapeutics discovery

MAP

Mutation Allostery Pharmacology (MAP) drug discovery engine — identifies oncogenic mutations across genes, confirms oncogenicity via cell and tumor models, and guides pharmacologic inhibition of mutant proteins while sparing wild-type; used to discover MasterKey inhibitors for genetically defined cancers including NSCLC and GBM

Capital (as filed)

Cash
$19.2M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$91.3M Jun 30, 2026
Operating cash flow
−$8.0M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$111M cash, runway into the second half of 2028 per the deep dive of Oct 7, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Black Diamond Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-10-08 Watch Black Diamond Therapeutics (BDTX) - Scientific Deep Dive for Silevertinib and Pipeline Products Silevertinib has real CNS activity but is priced at cash with an unfunded pivotal trial, afatinib-grade toxicity at the tested dose, and a leading competitor already ten months into a comparable Phase 3.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (10)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)